Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 18 , ISSUE 11 ( November, 2014 ) > List of Articles


Carbapenem resistant Gram-negative bacteremia in an Indian intensive care unit: A review of the clinical profile and treatment outcome of 50 patients

V. Ramasubramanian, Ravikant Porwal, Naga Rajesh

Keywords : Bacteremia in Indian intensive care unit, carbapenem resistant Gram-negative bacteremia, carbapenem resistant Klebsiella pneumoniae, multidrug-resistant bacteremia

Citation Information : Ramasubramanian V, Porwal R, Rajesh N. Carbapenem resistant Gram-negative bacteremia in an Indian intensive care unit: A review of the clinical profile and treatment outcome of 50 patients. Indian J Crit Care Med 2014; 18 (11):750-753.

DOI: 10.4103/0972-5229.144021

License: CC BY-ND 3.0

Published Online: 01-12-2008

Copyright Statement:  Copyright © 2014; The Author(s).


Background: Growing antimicrobial resistance and limited therapeutic options to treat carbapenem-resistant bacteremia prompted us to evaluate the clinical outcomes associated with healthcare-associated bacteremia. Methods: This was a retrospective observational study of carbapenem-resistant Gram-negative bacteremia performed at a tertiary care facility in Chennai, India between May 2011 and May 2012. Results: In our study, patients had mean 11.76 days of intensive care unit (ICU) care and mean time to onset of bacteremia was 6.4 days after admission. The commonest organism was Klebsiella pneumoniae (44%). Patients with combination treatment had lower mortality (44.8%) compared with colistin monotherapy (66.6%); (P = 0.35). Conclusion: Carbapenem resistant bacteremia is a late onset infection in patients with antibiotic exposure in the ICU and carries a 30 days mortality of 60%; K. pneumoniae is the most common organism at our center. Two drug combinations appear to carry a lower mortality compared with monotherapy.

PDF Share
  1. Untreatable: Report by CDC details today′s drug-resistant health threats. Available from: [Last accessed on 2014 Mar 01].
  2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
  3. Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: Treatment options with carbapenems compromised. J Assoc Physicians India 2010;58:147-9.
  4. Nair PK, Vaz MS. Prevalence of carbapenem resistant Enterobacteriaceae from a tertiary care hospital in Mumbai, India. J Microbiol Infect Dis 2013;3:207-10.
  5. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in North India. Indian J Med Res 2006;124:95-8.
  6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement; M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
  7. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-40.
  8. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009;37:1463-9.
  9. Parthasarathy P. Risk factors and mortality in carbapenem resistant gram negative bacteremias: A retrospective analysis from a tertiary health care setting in India. Poster Abstract 1608, ID Week; 2013.
  10. Ghafur A, Kannaian P, Tayade A. Clinical study of carbapenum-sensitive and carbapenem-resistant bacteraemia in neutropenic and non-neutropenic patients: The first series from India. Abstract P 1368, 23rd ECCMID; 2013.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.